Clinical trial
Participation is governed by a specific research protocol, eligibility criteria, informed consent, and a study team. A trial can investigate safety or treatment questions without making a therapy broadly available.
Atlas status: context-sensitive
Last updated: 21 August 2026
International access map / independent orientation
Global Clinic Atlas
A practical way to distinguish licensed care, research pathways, and informal claims when considering ibogaine or ibogaine-adjacent care beyond the traditional Mexican retreat scene.
01 / orientation
Start with the pathway, not the destination.
Country names alone do not establish whether a program is licensed, medically supervised, available through research, or operating in a setting without clear regulation. The broader Beyond Mexico Ibogaine landscape is best read as a changing set of legal and clinical pathways rather than a simple directory of places.
Authorized access
Some systems provide routes such as special access, compassionate use, or case-by-case authorization. These routes are distinct from ordinary commercial availability and can change with policy.
Licensed clinical setting
A clinic licence may regulate the facility or professional practice, but it does not automatically mean ibogaine itself is approved for a particular indication. Both questions need checking.
02 / verification stream
An access claim needs several checks.
For grounded context on cross-border decisions, use the site’s main ibogaine pathways overview alongside the jurisdiction-specific steps below. This page identifies models and questions; it does not recommend providers or assess individual suitability.
01
Identify the legal status of the substance.
Ibogaine may be controlled, restricted, available only for approved research, or treated differently from iboga plant material. The ibogaine overview helps distinguish the compound from broader cultural and botanical references, but official local sources remain the decisive check.
02
Separate facility regulation from treatment authorization.
A regulated hospital, outpatient practice, or addiction service can still be unable to offer an unapproved medicine outside a study or special-access process. Ask what authority governs the specific intervention.
03
Locate the oversight layer.
Clinical oversight is meaningful only when the setting can clearly describe medical assessment, monitoring, escalation procedures, and the role of licensed professionals. A general comparison of care structures appears in the clinical model comparison.
04
Record the date and the source.
Regulation, trial recruitment, and special-access policies can change. Treat dated official material as more useful than undated promotional language, and revisit it before acting.
03 / jurisdiction scan
Selected pathways outside the retreat model.
This scan is intentionally selective. It describes notable regulatory or research contexts, not an exhaustive list of programs. Inclusion is not an endorsement, and absence does not establish that care is unavailable.
Brazil
Brazil is often discussed in relation to ibogaine because clinical interest and private treatment claims have been visible there. A visible treatment setting should not be assumed to be formally authorized for ibogaine on that basis alone. The relevant questions are the legal status of the substance, the facility’s local authorization, and whether medical monitoring is actually part of the stated model.
New Zealand
New Zealand has been cited in ibogaine discussions because access has historically been considered through a prescription-oriented framework rather than a broad retail market. The national medicines regulator’s Medsafe guidance and regulatory information is the appropriate starting point for current status, not legacy accounts of access.
South Africa
South Africa is another jurisdiction where treatment activity and public discussion have been reported. The existence of a provider market does not resolve questions about medicine scheduling, professional scope, emergency readiness, or the reliability of claimed clinical supervision. For people comparing options, the access and considerations framework can help organize those questions before interpreting any provider statement.
Canada and select European settings
In Canada, interest is often framed around clinical research and exceptional pathways rather than ordinary approval. Health Canada’s Special Access Program information explains that access to non-marketed drugs is exceptional and practitioner-led; it is not a general consumer route. Across Europe, legal status and research activity differ substantially by country, so a European location is not a single regulatory category.
“Licensed clinic” can describe a facility. It does not, by itself, establish approval, evidence, or safety for an ibogaine intervention.
04 / safety context
Where oversight is clear—and where it may not be.
Formal oversight is most legible in regulated research, hospital-linked care, or an explicitly authorized clinical pathway. In contrast, informal and unregulated settings may use clinical language without showing how assessment, monitoring, transfer, or accountability work in practice.
Ibogaine has been associated with cardiac safety concerns, including effects on cardiac rhythm. The U.S. National Library of Medicine’s clinical review of ibogaine toxicity describes why screening and risk context matter. That does not make a particular model appropriate for any person; it underscores why promotional claims cannot substitute for clinical judgment.
People evaluating claims about alcohol-related care can compare them with the narrower question posed in does ibogaine work for alcohol, while those focused on the United States can distinguish provider marketing from the separate landscape described by ibogaine treatment centers in the USA.
05 / field notes
Frequently asked questions
Does a country with ibogaine providers necessarily have approved ibogaine treatment?
No. Provider visibility, facility licensing, medicine approval, research authorization, and special-access eligibility are separate matters. A focused view of ibogaine treatment clinic models in Mexico illustrates why geography alone does not answer the oversight question.
What does “ibogaine-adjacent care” mean here?
It refers to models that may be connected to ibogaine research, assessment, recovery support, or other related pathways without necessarily offering ibogaine as an approved, routine treatment. The exact service and its legal basis should always be checked locally.
Can this atlas identify the right program for an individual?
No. It is an orientation tool, not medical or legal advice and not a referral service. Anyone beginning the location question can use where can I do ibogaine treatment as a starting prompt, then verify current rules and seek appropriate independent professional guidance.
Next checkpoint
Keep the questions visible.
This atlas is designed to make uncertainty easier to see: what is authorized, what is researched, what is informal, and what still needs verification.